CRL

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

Retrieved on: 
Thursday, November 9, 2023
Alnylam Pharmaceuticals, Telephone, Patisiran, Food, Cardiomyopathy, Amyloidosis, Patient, ATTR, FDA, New Drug Application, CRL, Symantec Endpoint Protection, Shanda, News

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of ARS Pharmaceuticals, Inc. (SPRY)

Retrieved on: 
Thursday, November 9, 2023
Telephone, Food, ARS, Allergy, FDA, Symantec Endpoint Protection, CRL, Adrenaline, Food and Drug Administration, News

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of ARS Pharmaceuticals, Inc. ("ARS") (NASDAQ: SPRY) concerning possible violations of federal securities laws.
  • The CRL indicated ARS must complete additional studies on “neffy” before the FDA can consider further the drug’s approval.
  • In particular, the FDA indicated ARS must provide data concerning repeated doses of nasal epinephrine in individuals experiencing allergic reactions.
  • Following this news, ARS’ stock price fell by $4.52 per share, or approximately 61% to close at $2.92 per share.

Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration

Retrieved on: 
Monday, December 18, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Genetics, Life expectancy, NYSE, DNA, GMP, Food, European Medicines Agency, CRISPR Therapeutics, Therapy, CDMO, Vertex, EMA, Patient, FDA, Blood, Health Products Regulatory Authority, Cas9, CRL, CRISPR, Oxygen, SCD, HPRA, News, Pharmaceutical industry, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel]).

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel]).
  • “We are pleased to reach this milestone working hand-in-hand with Vertex to manufacture the world’s first gene-edited therapy.
  • Charles River provides cell and gene-modified cell therapy developers with an efficient, robust, and scalable process to swiftly transition autologous and allogeneic programs to clinic and commercialization with one production partner.
  • Combined with the Company’s legacy testing capabilities, Charles River offers an industry-leading “concept-to-cure” advanced therapies solution.

Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening

Retrieved on: 
Tuesday, December 12, 2023
Research, Medical Devices, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Oncology, CDX, Corporation, NYSE, PDX, Sarcoma, Collection, Database, Patient, Tumor microenvironment, Medicine, Thymoma, TME, Therapy, Drug discovery, Cancer, CRL, 3D, Doctor of Philosophy, Medical imaging, Pharmaceutical industry

This enhanced offering will provide Charles River clients with access to CELLphenomics ’ proprietary 3D tumor model platform, PD3D® , expanding Charles River’s 3D in vitro testing services to further optimize oncological approaches for its clients.

Key Points: 
  • This enhanced offering will provide Charles River clients with access to CELLphenomics ’ proprietary 3D tumor model platform, PD3D® , expanding Charles River’s 3D in vitro testing services to further optimize oncological approaches for its clients.
  • CELLphenomics’ core competency is the establishment and cultivation of complex patient-derived 3D cell culture models (PD3D) from various solid tumor tissues.
  • Leveraging CELLphenomics technology, Charles River will now have a novel in vitro option for identifying therapeutics for rare and ultra-rare disease types.
  • The agreement will also provide CELLphenomics access to Charles River’s genomically annotated and in vivo characterized cancer model database to develop PD3D models.

Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, Display resolution, Dystonia, NYSE, DNA, GMP, Hope, Entrepreneurship, Tecmar, Degenerative disease, CDMO, Patient, Hereditary spastic paraplegia, Visual impairment, Genetic testing, Muscle weakness, Spasticity, Golden, Seizure, Cerebellar ataxia, Partnership, CRL, Doctor of Philosophy, Parent, HQ, Life, DSM-IV codes, Intellectual disability, Pharmaceutical industry, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures for rare diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures for rare diseases, today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio to simplify complex supply chains and meet growing demand for plasmid DNA, viral vector, and cell therapy services.
  • Combined with the Company’s legacy testing capabilities, Charles River offers a comprehensive “concept-to-cure” advanced therapies solution.
  • - Golden Whitrod, Tallulah Moon’s mother and Co-Founder and President, Genetic Cures for Kids, Inc.

Charles River Laboratories to Present at Evercore ISI Investor Conference

Retrieved on: 
Monday, November 27, 2023
Biotechnology, General Health, Medical Devices, Health, Pharmaceutical, NYSE, Conference, CRL, Pharmaceutical industry, Canal

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th, at 9:10 a.m.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th, at 9:10 a.m.
  • Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.
  • A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com .
  • A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks.

Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products

Retrieved on: 
Thursday, November 16, 2023
Research, Medical Devices, Genetics, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, NYSE, GMP, Good manufacturing practice, Risk, Clinical trial, Cryopreservation, CRL, Good, Pharmaceutical industry

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its CliniPrime™ suite of Good Manufacturing Practice (GMP)-compliant offerings with the launch of CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its CliniPrime™ suite of Good Manufacturing Practice (GMP)-compliant offerings with the launch of CliniPrime Cryopreserved Leukopaks for cell therapy development and manufacturing.
  • The launch of CliniPrime Cryopreserved Leukopaks completes an already robust portfolio of GMP-compliant leukopaks from Charles River.
  • Charles River provides cellular products and services, creating collaborative relationships with clients as they progress their programs through the development cycle.
  • Clients now have rapid access to fresh or cryopreserved leukopaks to meet any specific program needs.” – Steve Phagoo, Executive Director, Global Cell Solutions, Charles River

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Retrieved on: 
Monday, November 13, 2023
Software, Research, General Health, Pharmaceutical, Oncology, Medical Devices, Technology, Artificial Intelligence, Science, Biotechnology, Neurology, Health, World Health Organization, Multiple myeloma, NYSE, Causal AI, Prevalence, Biology, PDX, Digital twin, IND, WHO, HD, PD, Multimedia, Prostate cancer, Pharmacology, Therapy, Dementia, Drug discovery, Neurodegenerative disease, CRL, Cancer, Partnership, Biomarker, AI, ADME, HIV disease progression rates, DSM-IV codes, Pharmaceutical industry, Medical imaging, Causality (physics), Logica

Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia , a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™ , Charles River’s Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Aitia , a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™ , Charles River’s Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
  • There are currently no known cures for these diseases, and the prevalence of all three diseases rises year-over-year.
  • As part of the partnership, Charles River has made an equity investment in Aitia.
  • More recently, Charles River and Related Sciences announced a multi-program collaboration to apply Logica across several previously undrugged targets.

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Alzheimer's disease, Multiple myeloma, Huntington's disease, Research, NYSE, Causal AI, Prevalence, Parkinson's disease, Biology, PDX, Digital twin, IND, HD, PD, Artificial intelligence, WHO, Patient, Prostate cancer, Pharmacology, Therapy, Dementia, Drug discovery, Neurodegenerative disease, CRL, Cancer, Partnership, Biomarker, AI, ADME, HIV disease progression rates, DSM-IV codes, Flagship, Pharmaceutical industry, Medical imaging, Causality (physics), Logica, Charles River

There are currently no known cures for these diseases, and the prevalence of all three diseases rises year-over-year.

Key Points: 
  • There are currently no known cures for these diseases, and the prevalence of all three diseases rises year-over-year.
  • We are excited to join forces with Charles River, leveraging their decades of industry expertise in research to fuel our R&D efforts."
  • Additionally, Charles River and Aitia have signed a strategic partnership agreement, focused on the development of a patient-derived xenograft (PDX) Digital Twin to predict the best tumor models for in vivo oncology research.
  • More recently, Charles River and Related Sciences announced a multi-program collaboration to apply Logica across several previously undrugged targets.

Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023

Retrieved on: 
Thursday, November 9, 2023
Research, Medical Devices, Neurology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Psilocybin, Duchenne muscular dystrophy, DC, NYSE, Region, UBE3A, ASO, Neuron, Booth, Treatment, Neurodegenerative disease, Microglia, Doctor of Philosophy, Society, CRL, Artificial intelligence, Mouse, Chemotaxis, Functional ultrasound imaging, Drug discovery, Partnership, Machine learning, B cell, Master of Science, Phenotype, Phagocytosis, Patient, Pharmaceutical industry, Medical device, Medical imaging, Flour, Neuroscience, Logica

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN).

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN).
  • “Neuroscience is one of the most complex areas of drug discovery,” Antti Nurmi, PhD, MSc, Regional General Manager, Europe, Charles River.
  • These innovations will ultimately accelerate success in this critical field of drug development.”
    Throughout the conference, Charles River experts will present posters and host discussions on the latest developments in neuroscience research and innovative approaches to tackling neurodegenerative disorders.
  • Additionally, experts will be available at Booth #1717 for meetings with those interested in discussing neuroscience research and drug discovery.